Emerging trends in sacubitril/valsartan research: A bibliometric analysis of the years 1995-2021.

Autor:	Lai P; Department of Cardiology, The First Hospital of Gannan Medical University, Gannan Medical University, Ganzhou, China.; Institute of Experimental Cardiovascular Research, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Xue JH; Department of Physiology, School of Basic Medical Sciences, Gannan Medical University, Ganzhou, China., Xie MJ; Department of General Medicine, Lingyun Community Health Service Center of Xuhui District, Shanghai, China., Ye JH; School of Basic Medical Sciences, Gannan Medical University, Ganzhou, China., Tian KJ; Department of Cardiology, The First Hospital of Gannan Medical University, Gannan Medical University, Ganzhou, China., Ling JY; Department of Cardiology, The First Hospital of Gannan Medical University, Gannan Medical University, Ganzhou, China., Zhong WT; Department of Cardiology, The First Hospital of Gannan Medical University, Gannan Medical University, Ganzhou, China., Chen D; Department of Cardiology, The First Hospital of Gannan Medical University, Gannan Medical University, Ganzhou, China., Zhong YM; Department of Cardiology, The First Hospital of Gannan Medical University, Gannan Medical University, Ganzhou, China.; Department of Cardiology, Key Laboratory of Prevention and Treatment of Cardiovascular and Cerebrovascular Diseases, Ministry of Education, First Affiliated Hospital of Gannan Medical University, Gannan Medical University, Ganzhou, China., Liao YL; Department of Cardiology, The First Hospital of Gannan Medical University, Gannan Medical University, Ganzhou, China.; Department of Cardiology, Key Laboratory of Prevention and Treatment of Cardiovascular and Cerebrovascular Diseases, Ministry of Education, First Affiliated Hospital of Gannan Medical University, Gannan Medical University, Ganzhou, China.
Jazyk:	angličtina
Zdroj:	Medicine [Medicine (Baltimore)] 2022 Aug 05; Vol. 101 (31), pp. e29398.
DOI:	10.1097/MD.0000000000029398
Abstrakt:	Background: Sacubitril/valsartan has been approved for the treatment of heart failure (HF) patients with reduced ejection fraction; since then, it gradually became a new star drug in the therapy of HF. Nevertheless, the effectiveness of sacubitril/valsartan remains under investigation. Thus far, only a few bibliometric studies have systematically analyzed the application of sacubitril/valsartan. Methods: Publications on sacubitril/valsartan were retrieved from the Web of Science Core Collection on April 29, 2021. Data were analyzed using Microsoft Excel 2019 (Redmond, WA), VOS viewer (Redmond, WA), and Cite Space V (Drexel University, Philadelphia, PA). Results: A total of 1309 publications on sacubitril/valsartan published from 1995 to 2021 were retrieved. The number of publications regarding sacubitril/valsartan increased sharply in the last 6 years (2015-2021), and American scholars authored >40% of those publications. Most were published in the European Journal of Heart Failure, the United States was the bellwether with a solid academic reputation in this area. Solomon published the highest number of related articles and was the most frequently cited author. "Heart failure" was the leading research hotspot. The keywords, "inflammation," "fibrosis," and "oxidative stress" appeared most recently as research fronts. Conclusions: Research attention should be focused on clinical trial outcomes. Considering its effectiveness in HF, the mechanisms and further applications of sacubitril/valsartan may become research hotspots in the future and should be closely examined. Competing Interests: The authors have no conflicts of interest to disclose. (Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu